The Fibrolamellar Cancer Foundation (FCF) and Dracen Pharmaceuticals announce initiation of a phase I/II study of DRP-104 in combination with Durvalumab in patients with fibrolamellar carcinoma (FLC)
February 14, 2024
PDF Version

FCF establishes partnership with Dracen Pharmaceuticals
July 11, 2023
Visit FCF website

Dracen Pharmaceuticals Announces Oral Presentation at Festival of Biologics World Immunotherapy Congress 2022
March 18, 2022
PDF Version

Dracen Announces DRP-104 (sirpiglenastat) Presentation at ASCO 2021 Virtual Annual Meeting
June 3, 2021
PDF Version

Dracen Announces DRP-104 (sirpiglenastat) Presentations at AACR Virtual Annual Meeting
April 12, 2021
PDF Version

Dracen Announces Clinical Collaboration with Merck
March 8, 2021
PDF Version

Dracen Pharmaceutical’s DRP-104 Granted U.S. FDA Fast Track Designation for the treatment of Non-Small Cell Lung Cancer
October 27, 2020
PDF Version

Dracen Pharmaceuticals Announces the Initiation of First-in-human Study of DRP-104 in Adult Patients With Advanced Solid Tumors
September 25, 2020
PDF Version

Dracen announces two DRP-104 presentations at AACR
June 22, 2020
PDF Version

Dracen Pharmaceuticals announces DRP-104 presentations at the 2019 Society of Immunotherapy of Cancer (SITC) Meeting
November 8, 2019
PDF Version

Dracen Announces AACR Presentation
April 12, 2018
PDF Version

Dracen Closes Financing to Advance Immunometabolism Pipeline
March 22, 2018
PDF Version

Dracen Licenses Immunometabolism Platform
January 11, 2018
PDF Version